Astrid Botty van den Bruele
Overview
Explore the profile of Astrid Botty van den Bruele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
104
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van den Bruele A, Ren Y, Thomas S, Ntowe K, Rosenberger L, Menendez C, et al.
Breast Cancer Res Treat
. 2025 Feb;
PMID: 40016543
Background: The risk of developing breast cancer up to age 80 for women with BRCA1/2 mutations is approximately 69-72%. The risk estimates, however, become labile in the later years of...
2.
Wang T, Jones T, Thomas S, van den Bruele A, Rosenberger L, Chiba A, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2459692.
PMID: 39946126
Importance: Current practices in axillary treatment for patients with breast cancer who receive a mastectomy for node-positive disease are unknown. For patients who receive postmastectomy radiotherapy (PMRT), the addition of...
3.
van den Bruele A, Williams A, Weiss A
Ann Surg Oncol
. 2025 Jan;
32(4):2265-2270.
PMID: 39806047
No abstract available.
4.
Singh P, Agnese D, Amin M, Barrio A, van den Bruele A, Burke E, et al.
Ann Surg Oncol
. 2024 Nov;
32(2):899-911.
PMID: 39538100
Bilateral risk-reducing mastectomy (BRRM) is the surgical removal of both breasts to reduce the risk of cancer. In this Society of Surgical Oncology position statement, we review the literature addressing...
5.
Limberg J, Jones T, Thomas S, Ntowe K, Dalton J, van den Bruele A, et al.
Ann Surg Oncol
. 2024 Sep;
31(13):8813-8820.
PMID: 39230856
Background: Axillary management after neoadjuvant chemotherapy (NAC) is evolving but axillary lymph node dissection (ALND) remains the standard of care for patients with residual nodal disease. The results of the...
6.
Record S, Thomas S, Dalton J, van den Bruele A, Chiba A, DiLalla G, et al.
Ann Surg Oncol
. 2024 Aug;
31(13):8802-8812.
PMID: 39198350
Background: Older breast cancer patients represent a heterogeneous population. Studies demonstrate that sentinel lymph node biopsy (SLNB) omission may be appropriate in some clinical scenarios, yet patients with triple-negative breast...
7.
Parrish K, Thomas S, Cartwright S, van den Bruele A, Zasloff R, DiLalla G, et al.
Ann Surg Oncol
. 2024 Aug;
31(12):8057-8067.
PMID: 39158638
Background: Patients with inflammatory breast cancer (IBC) have worse survival compared with stage III non-IBC matched cohorts; however, the prognostic significance of achieving pathologic complete response (pCR) in the setting...
8.
Dalton J, Crowell K, Ntowe K, van den Bruele A, DiNome M, Rosenberger L, et al.
Ann Surg Oncol
. 2024 Jul;
31(11):7621-7633.
PMID: 39014162
Background: The utility of sentinel lymph node biopsy (SLNB) in older patients remains controversial. Advancements in human epidermal growth factor receptor 2 (HER2)-directed therapy have revolutionized disease response rates and...
9.
van den Bruele A, Weiss A
Ann Surg Oncol
. 2024 Jul;
31(9):5479-5482.
PMID: 38969855
No abstract available.
10.
Montagna G, Mrdutt M, Sun S, Hlavin C, Diego E, Wong S, et al.
JAMA Oncol
. 2024 Apr;
10(6):793-798.
PMID: 38662396
Importance: Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse....